circadian rhythm raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-03-12 and is reviewed periodically as new material appears.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to pale yellow solid | Visual description varies with purity and source |
| Solubility | Soluble in DMSO and ethanol; poorly soluble in water | Organic stock solutions are common in research |
| Typical storage | -20 °C, desiccated, protected from light | Avoid repeated freeze-thaw cycles |
| Typical analytical method | LC-MS or HPLC-UV | Reference standards are needed for quantification |
| Molar mass | Approximately 437.9 g/mol | Calculated from the reported free-base formula |
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
The broadcast pattern covered an area of about 100 degrees in a roughly fan-shaped area, with a smaller side lobe to the rear, courtesy of the reflectors, and much smaller ones to the sides. When the signal reflected off the ground it underwent a ½ wavelength phase-change, which caused it to interfere with the direct signal. The result was a series of vertically stacked lobes about 5 degrees wide from 1 degree off the ground to the vertical. The system was later expanded by adding another set of four additional antennas closer to the ground, wired in a similar fashion. The receiver consisted of an Adcock array consisting of four 240 foot (73 m) tall wooden towers arranged at the corners of a square. Each tower had three sets (originally two) of receiver antennas, one at 45, 95 and 215 feet off the ground. The mean height of the transmitter stack was 215 feet, which is why the topmost antenna was positioned at the same altitude in order to produce a reception pattern that was identical to the transmission. A set of motor-driven mechanical switches allowed the operator to select which antenna was active. The output of the selected antenna on each of the four towers was sent to a single radiogoniometer system (not Watt's own huff-duff solution). By connecting the antennas together in X-Y pairs the horizontal bearing could be measured, while connecting together the upper and lower antennas allowed the same goniometer to be used to measure the vertical angle. Two physical layout plans were used, either 'East Coast' or 'West Coast'.
== History == The bifurcated needle was invented in 1965 by microbiologist Benjamin Rubin, created from the eyelet of a sewing machine needle and initially intended for multiple pressure vaccination. It was repurposed specifically for smallpox vaccination by D.A. Henderson in 1967, who was the first to suggest holding the needle at a right angle to the skin and making 15 light, rapid punctures. This is now referred to as the multiple puncture method. Because of the forked construction, the needle does not penetrate deeply into the skin. The multiple puncture method was also found to be more successful for smallpox vaccination. The bifurcated needle was adopted given its efficiency and cost effectiveness in comparison to the alternative jet injector previously in use. Bifurcated needles cost $5 USD per thousand at the time, and could be indefinitely boiled and reused. Their cost effectiveness and efficacy played an important role in the eradication effort's success; without the bifurcated needle, the eradication program may have failed. Rubin estimated that it was used to administer 200 million vaccinations per year during the final years of the campaign. An honorary, unofficial recognition was established by D.A. Henderson called the Order of the Bifurcated Needle. Individuals who played key roles in the global smallpox eradication effort were awarded a lapel badge designed from a bifurcated needle twisted into a circle, symbolizing the program's goal of Target Zero.
A systematic and independent examination of trial-related activities and documents to determine whether the evaluated trial-related activities were conducted, and the data were recorded, analyzed, and accurately reported according to the protocol, sponsor's standard operating procedures (SOPs), good clinical practice (GCP), and the applicable regulatory requirement(s). (ICH E6) Audit certificate
FVIII concentrated from donated blood plasma, or recombinant FVIII can be given to hemophiliacs to restore hemostasis. Bypassing agents such as recombinant FVIIa can be used in acquired hemophilia. Antibody formation to factor VIII can also be a major concern for patients receiving therapy against bleeding; the incidence of these inhibitors is dependent of various factors, including the factor VIII product itself.
== Further information == Betz Laboratories (1976). Handbook of Industrial Water Conditioning (7th ed.). Betz Laboratories. Ion Exchangers (K. Dorfner, ed.), Walter de Gruyter, Berlin, 1991. C. E. Harland, Ion exchange: Theory and Practice, The Royal Society of Chemistry, Cambridge, 1994. Friedrich G. Helfferich (1962). Ion Exchange. Courier Dover Publications. ISBN 978-0-486-68784-1. {{cite book}}: ISBN / Date incompatibility (help) Kemmer, Frank N. (1979). The NALCO Water Handbook. McGraw-Hill. Ion exchange (D. Muraviev, V. Gorshkov, A. Warshawsky), M. Dekker, New York, 2000. A. A. Zagorodni, Ion Exchange Materials: Properties and Applications, Elsevier, Amsterdam, 2006. SenGupta, Arup K. (2017). Ion exchange in environmental processes: fundamentals, applications and sustainable technology. Hoboken, NJ. ISBN 978-1-119-42125-2. OCLC 1001290476.{{cite book}}: CS1 maint: location missing publisher (link) Dr., I., & Luqman, M. (2012). Ion Exchange Technology I : Theory and Materials. Springer Netherlands. Harland, C. E. (1994). Ion exchange : theory and practice (2nd ed.). The Royal Society of Chemistry.
Sources: en.wikipedia.org
NMD is used to protect the cell from producing harmful truncated proteins resulting from nonsense mutations. NMD has recently been found to impact cell differentiation of stem cells due to the decay of mRNA encoding factors. The NMD pathway differentiates premature termination codons (PTC) from normal stop codons by only attacking presliced mRNA strands. This means that the mRNA contains exons and introns in the strand. This is because the machinery for NMD recognizes exon-junctions complexes. Unlike translational termination, NMD utilizes many intermediate protein complexes to achieve mRNA decay. The initial step of NMD is the construction of the SURP complex. This complex is composed of 4 proteins: SMG-1, Upf1, eRF1, and eRF3 (SURF). The complex is formed when Upf1 binds to SMG-1, which then clamps onto the eRF1 and eRF3 termination complex. The SURF complex then associates with a downstream complex composed of Upf2, Upf3, and EJC to create a new complex: Decay-Inducing Complex (DECID). Upon the joining of the two complexes, the DECID complex dissociates eRF1, eRF3, and the ribosome. The new complex contains EJC, Upf2, Upf3, SMG-1, and a phosphorylated Upf1. The phosphorylated Upf1 protein attracts additional SMG proteins, which are in the endonuclease enzymatic family. The SMG protein then cleaves the mRNA strand near the premature stop codon. This event is essentially decapping the protective head group on the mRNA strand, which will cause the rest of the strand to be degraded by exosomes.
Mass spectrometry (MS) is an analytical technique that is used to measure the mass-to-charge ratio of ions. The results are presented as a mass spectrum, a plot of intensity as a function of the mass-to-charge ratio. These spectra are used to determine the elemental or isotopic signature of a sample, the masses of particles and of molecules, and to elucidate the chemical identity or structure of molecules and other chemical compounds. Mass spectrometry is used in many different fields and is applied to pure samples as well as complex mixtures.
Some scholars believe Christian elements are deeply embedded in Druze beliefs, introduced through Isma'ili traditions. This is evident in the Druze creed, which deifies al-Hākim bi Amrillāh. The initiation text, "Mīthāq Walī al-Zamān" (Pact of Time Custodian), which begins with, "I rely on our Moula Al-Hakim the lonely God, the individual, the eternal,... Obedience of almighty Moulana Al-Hākim, exalted be him and that obedience is worship and that he does not have any partners ever, present or coming", closely resembles Christian beliefs about Jesus' divinity. The Druze also view figures like Jesus, al-Hākim bi Amrillāh, and Hamza ibn Ali as the Messiah or Mahdi. They believe al-Hākim will return at the end of times to judge the world and establish his kingdom, while Hamza ibn Ali is considered a reincarnation of Jesus, the Universal Mind 'Aql, closely associated with al-Hākim. Druze doctrine regards Christianity, Judaism, and Islam as preceding religions that embody different manifestations of Druzism, which they consider superior to all. According to Druze beliefs, Adam and Jesus hold a unique status among prophets, sharing in divine essence. The Druze conception of Jesus ('Īsa ibn-Yūsuf) differs somewhat from the portrayal in the New Testament; he resembles the Muslim interpretation of Jesus as envisioned by the ancient Docetae sect, who believed that Christ suffered only in appearance. Christian influences are evident in the writings of the Druze missionary Baha al-Din al-Muqtana (d. 1042).
Patients being treated for osteoporosis or non-malignant bone disease with oral bisphosphonates/quarterly or yearly infusions of intravenous bisphosphonates for >5 years Patients being treated for osteoporosis or non-malignant bone disease with bisphosphonates/denosumab for any length of time as well as being treated with systemic glucocorticoids Patients being treated with anti-resorptive/anti-angiogenic drugs/both as part of cancer management Previous MRONJ diagnosis "N.B. Patients who have taken bisphosphonate drugs at any time in the past and those who have taken denosumab in the last nine months are allocated to a risk group as if they are still taking the drug."
=== Metabolism === CoQ10 is metabolized in all tissues, with the metabolites phosphorylated in cells. CoQ10 is reduced to ubiquinol during or after absorption in the small intestine. It is absorbed by chylomicrons, and redistributed in the blood within lipoproteins. Its elimination occurs via biliary and fecal excretion.
Sources: en.wikipedia.org
== Use as a protein and peptide vector == MBP is used to increase the solubility of recombinant proteins expressed in E. coli. In these systems, the protein of interest is often expressed as a MBP-fusion protein, preventing aggregation of the protein of interest. The mechanism by which MBP increases solubility is not well understood. In addition, MBP can itself be used as an affinity tag for purification of recombinant proteins. The fusion protein binds to amylose columns while all other proteins flow through. The MBP-protein fusion can be purified by eluting the column with maltose. Once the fusion protein is obtained in purified form, the protein of interest is often cleaved from MBP with a specific protease and can then be separated from MBP by affinity chromatography. A first study of the relations between structure and functions of MBP was performed by random insertion of a short DNA fragment, coding for a BamHI restriction site, into the malE gene. Some of the insertions affected the functions of MBP whereas others were permissive. The permissive sites that were internal to MBP, were used to insert antigenic peptides and challenge the immune response in mice. The 3'-OH terminal insertions were used to create fusion proteins and develop the use of MBP as an affinity handle for the purification of foreign proteins and peptides by affinity chromatography on cross-linked amylose and elution with maltose in mild physico-chemical conditions. Several plasmid vectors were developed to facilitate the expression and purification of such fusion proteins.
Another application of CE in forensics is ink analysis, where the analysis of inkjet printing inks is becoming more necessary due to increasingly frequent counterfeiting of documents printed by inkjet printers. The chemical composition of inks provides very important information in cases of fraudulent documents and counterfeit banknotes. Micellar electrophoretic capillary chromatography (MECC) has been developed and applied to the analysis of inks extracted from paper. Due to its high resolving power relative to inks containing several chemically similar substances, differences between inks from the same manufacturer can also be distinguished. This makes it suitable for evaluating the origin of documents based on the chemical composition of inks. It is worth noting that because of the possible compatibility of the same cartridge with different printer models, the differentiation of inks on the basis of their MECC electrophoretic profiles is a more reliable method for the determination of the ink cartridge of origin (its producer and cartridge number) rather than the printer model of origin. A specialized type of CE, affinity capillary electrophoresis (ACE), utilizes intermolecular binding interactions to understand protein-ligand interactions. Pharmaceutical companies use ACE for a multitude of reasons, with one of the main ones being the association/binding constants for drugs and ligands or drugs and certain vehicle systems like micelles. It is a widely used technique because of its simplicity, rapid results, and low analyte usage.
Also, to bring the buildings up to the District of Columbia's current building code, the buildings required new plumbing, new electrical, HVAC, water, and fire suppression systems, new accessibility features for the disabled (including in one elevator), and the renovation has found higher levels of asbestos and a higher water table than was expected while also finding lead contamination in the ground underneath the buildings (which was not anticipated). Powell and the Federal Reserve have denied that the building designs included dining rooms or elevators for use only by VIPs or Federal Reserve Governors, rooftop terraces, and have asserted that the only proposed water features that had been included in the initial renovation plan for the East Building were eliminated. Additionally, both the East Building and the Eccles Building are included in the District of Columbia Inventory of Historic Sites while the East Building is also included in the National Register of Historic Places, and some of the cost overruns are due to changes to the design plans to comply with historic preservation laws for maintaining historic buildings and their appearance. The Eccles Building and East Building are also located on the National Mall, and the District's building code has a height restriction that requires that buildings not be taller than the United States Capitol, which required underground construction to expand one of the buildings to include a basement and an addition to the other for greater office space.
High throughput analysis is a significant advantage in the use of DMF systems, but means that they are particularly susceptible to cross contamination between experiments. As a result, the coupling of DMF with mass spectrometry often requires the integration of a variety of methods to prevent cross contamination such as multiple washing steps, biologically compatible surfactants, and or super hydrophobic surfaces to prevent droplet adsorption. In one example, a reduction in cross contaminant signal during the characterization of an amino acid required 4-5 wash steps between each sample droplet for the contamination intensity to fall below the limit of detection.
Sources: en.wikipedia.org
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.
The compound is generally handled as light-sensitive and stored cold and dry. Stability in solution depends on solvent, concentration, and storage time. Specific degradation rates are not fully standardized.
Limited water solubility affects formulation for cell and animal studies. Organic co-solvents are often used to dissolve it. Precipitation can confound assay results if not controlled.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.